JIUQUAN

Gansu set to present its global calling card

Retrieved on: 
Wednesday, September 6, 2023
Poverty, International, Tourism, Yang Pass, Culture, Silk, Linxia Hui Autonomous Prefecture, Multimedia, Aircraft, Jiuquan Satellite Launch Center, Organization, China Daily, Mogao Caves, Radio, City, Belt, Crescent, Silk Road, Conference, Television, Entertainment

BEIJING, Sept. 6, 2023 /PRNewswire/ -- A news report from China Daily:

Key Points: 
  • The Gansu Department of Culture and Tourism attaches great importance to publicity in creating the expo's ambience and making more people aware of the event.
  • As an example for inheriting culture and driving tourism, Dunhuang is important to Chinese culture and to tourism throughout the province.
  • Taking cultural tourism as its primary industry and focusing on projects, Jiuquan has joined a development consensus among 14 cities and prefectures in Gansu.
  • As a result, immersive performances supported by new technologies and new business models are being widely introduced into the cultural tourism field of Gansu.

Qilian International Holding Group Limited Signs Agreement with District Government, Settling the Project in Local High-tech Zone

Retrieved on: 
Thursday, August 5, 2021
People, Company, Chief executive officer, Research, Industry, Phrase, Keita Integrated Development Project, Technology, Degenerative disease, United States, Breeding, Sichuan, Private Securities Litigation Reform Act, Review, Project, Industrialisation, Fertilizer, Anticoagulant, Sale, SEC, Agreement, Nasdaq, Income, Death, Marketing, Conference, GLOBE, Fine chemical, Pharmaceutical industry

Pursuant to the Agreement, the Companys new pig by-product processing facility (the Project) will be located in Tongnan High-tech Zone.

Key Points: 
  • Pursuant to the Agreement, the Companys new pig by-product processing facility (the Project) will be located in Tongnan High-tech Zone.
  • Since 2020, the Company's heparin sodium industrialization development plan has received high attention from local and neighboring local governments.
  • In March 2021, the Project was listed as one of key investment projects by Chongqing Tongnan High-Tech Zone.
  • Qilian International Holding Group Limited, headquartered in Gansu, China, is a pharmaceutical and chemical products manufacturer in China.

Qilian International Holding Group Limited Enters into Investment Agreement for Pig By-product Processing Project in Chongqing

Retrieved on: 
Friday, July 9, 2021
Western China, Administrative divisions of China, Geography of China, Glycosaminoglycans, Heparins, Geography of Asia, Chongqing, Gansu, Qilian Mountains, Pork

The Project is expected to receive preferential policies from the government at the national, municipal and local levels.

Key Points: 
  • The Project is expected to receive preferential policies from the government at the national, municipal and local levels.
  • Mr. Zhanchang Xin, Chairman and CEO of the Company, commented, We are very pleased to work with CJT on the Project.
  • As a key area for pig breeding and pork production in China, Chongqing has sufficient raw materials for the production of heparin sodium preparations.
  • Qilian International Holding Group Limited, headquartered in Gansu, China, is a pharmaceutical and chemical products manufacturer in China.

Qilian International Holding Group Limited Enters into Exclusive Agency Agreement with Kangzhiyuan to Boost Sales of Gan Di Xin®

Retrieved on: 
Wednesday, May 5, 2021
XC2, Pharmacy

In addition, Gan Di Xin\xc2\xae has unparalleled taste and efficacy compared with traditional antitussive and expectorant drugs, making it an upgraded product among similar drugs.\nMr.

Key Points: 
  • In addition, Gan Di Xin\xc2\xae has unparalleled taste and efficacy compared with traditional antitussive and expectorant drugs, making it an upgraded product among similar drugs.\nMr.
  • Zhanchang Xin, Chairman and CEO of the Company, commented, \xe2\x80\x9cWe are very pleased to cooperate with Kangzhiyuan.
  • Previously, we marketed Gan Di Xin\xc2\xae mainly through third-party platforms in towns such as healthcare centers, individual clinics, and pharmacies.
  • We believe the national marketing channels and sales network of Kangzhiyuan will greatly assist us in achieving record sales for the compound licorice lozenges product.

Qilian International Holding Group Limited Announces Inclusion of 16 Products into China's National Reimbursement Drugs List

Retrieved on: 
Tuesday, April 13, 2021

In addition, 10 out of these 16 products have been included in the latest version of the National Essential Medicines List in China.\nNational Reimbursement Drug List is the list of products eligible for reimbursement in China, as maintained by the National Healthcare Commission of China.

Key Points: 
  • In addition, 10 out of these 16 products have been included in the latest version of the National Essential Medicines List in China.\nNational Reimbursement Drug List is the list of products eligible for reimbursement in China, as maintained by the National Healthcare Commission of China.
  • The National Essential Medicines List is one of the core contents of the essential medicines system.
  • Zhanchang Xin, Chairman and CEO of the Company, commented, \xe2\x80\x9cWe are excited to have 16 of our products included in the National Reimbursement Drugs List and 10 out of these 16 products also included in the National Essential Medicines List in China.
  • This means that our products may benefit from being included on such list and their market share grow consequently.\xe2\x80\x9d\nQilian International Holding Group Limited, headquartered in Gansu, China, is a pharmaceutical and chemical products manufacturer in China.

Qilian International Holding Group Limited CEO Receives Outstanding Entrepreneur Award

Retrieved on: 
Thursday, February 18, 2021
Sites along the Silk Road, Gansu, Inner Asia, MONGOLIA, Western China, Qilian Mountains, East Asia, Geography of Asia, Asia

Jiuquan, China, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Qilian International Holding Group Limited (Nasdaq: QLI) (the Company), a China-based pharmaceutical and chemical products manufacturer, today announced that its Chairman and Chief Executive Officer, Mr. Zhanchang Xin, received the Outstanding Entrepreneur Award from the Economic and Technological Development Zone of Jiuquan City in February 2021.

Key Points: 
  • Jiuquan, China, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Qilian International Holding Group Limited (Nasdaq: QLI) (the Company), a China-based pharmaceutical and chemical products manufacturer, today announced that its Chairman and Chief Executive Officer, Mr. Zhanchang Xin, received the Outstanding Entrepreneur Award from the Economic and Technological Development Zone of Jiuquan City in February 2021.
  • The Outstanding Entrepreneur Award is presented to chief executive officers of businesses in a wide range of industries and sectors with leadership skills, innovation, and entrepreneurial vision.
  • Mr. Xin commented: I am honored to receive the Outstanding Entrepreneur Award and I am proud of all the work our team has done over the years to make it happen.
  • Qilian International Holding Group Limited, headquartered in Gansu, China, is a pharmaceutical and chemical products manufacturer.

Qilian International Holding Group Limited to Triple Organic Fertilizer Production Capacity by March 2021

Retrieved on: 
Monday, February 8, 2021
Fertilizer, Gansu, Organic fertilizer, Organic food, Qilian Mountains, East Asia, Articles, Geography

The Company expects to triple its organic fertilizer production capacity upon completion of its first phase expansion.

Key Points: 
  • The Company expects to triple its organic fertilizer production capacity upon completion of its first phase expansion.
  • With a tripled production capacity, the Company has won bids for government organic fertilizer projects in Tibet, Gansu and Qinghai.
  • As each mu of arable land consumes 150-200 kilograms of organic fertilizer, the organic fertilizer market in China has tremendous potential.
  • Qilian International Holding Group Limited, headquartered in Gansu, China, is a pharmaceutical and chemical products manufacturer in China.

Qilian International Holding Group Limited Announces Full Exercise of Underwriters’ Over-Allotment Option

Retrieved on: 
Tuesday, January 19, 2021
Finance, Money, Financial markets, Stock market, Corporate finance, Initial public offering, Underwriting, Ticker symbol, Public offering

Gross proceeds of the Company's initial public offering, including the exercise of the overallotment, totaled $28.75 million, before deducting underwriting discounts and other related expenses.

Key Points: 
  • Gross proceeds of the Company's initial public offering, including the exercise of the overallotment, totaled $28.75 million, before deducting underwriting discounts and other related expenses.
  • The ordinary shares began trading on the Nasdaq Global Market on January 12, 2021 under the ticker symbol QLI.
  • Univest Securities, LLC acted as the representative of the underwriters and lead book-running manager for the Offering.
  • Qilian International Holding Group Limited, headquartered in Gansu, China, is a pharmaceutical and chemical products manufacturer in China.

Qilian International Holding Group Limited Announces Closing of Initial Public Offering

Retrieved on: 
Friday, January 15, 2021
Gansu, Inner Asia, MONGOLIA, Western China, Qilian Mountains, Underwriting, East Asia, Geography of Asia, Asia

Jiuquan, China, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Qilian International Holding Group Limited (the Company) (Nasdaq: QLI), a China-based pharmaceutical and chemical products manufacturer, today announced the closing of its initial public offering ("Offering") of 5,000,000 ordinary shares at a public offering price of US$5.00 per share.

Key Points: 
  • Jiuquan, China, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Qilian International Holding Group Limited (the Company) (Nasdaq: QLI), a China-based pharmaceutical and chemical products manufacturer, today announced the closing of its initial public offering ("Offering") of 5,000,000 ordinary shares at a public offering price of US$5.00 per share.
  • The Company received aggregate gross proceeds of US$25 million from this Offering, before deducting underwriting discounts and other related expenses.
  • Qilian International Holding Group Limited, headquartered in Gansu, China, is a pharmaceutical and chemical products manufacturer in China.
  • All statements other than statements of historical fact in this announcement are forward-looking statements, including but not limited to, the Company's proposed Offering.

Qilian International Holding Group Limited Announces Pricing of Initial Public Offering

Retrieved on: 
Tuesday, January 12, 2021
Qilian Mountains, Sites along the Silk Road, Initial public offering, Gansu, Pricing, East Asia, Geography of Asia, Asia

Jiuquan, China, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Qilian International Holding Group Limited (the Company), a China-based pharmaceutical and chemical products manufacturer, today announced the pricing of its initial public offering ("Offering") of 5,000,000 ordinary shares at a public offering price of US$5.00 per share.

Key Points: 
  • Jiuquan, China, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Qilian International Holding Group Limited (the Company), a China-based pharmaceutical and chemical products manufacturer, today announced the pricing of its initial public offering ("Offering") of 5,000,000 ordinary shares at a public offering price of US$5.00 per share.
  • In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 750,000 ordinary shares at the public offering price, less underwriting discounts.
  • The Offering is expected to close on or about January 14, 2021, subject to the satisfaction of customary closing conditions.
  • Qilian International Holding Group Limited, headquartered in Gansu, China, is a pharmaceutical and chemical products manufacturer in China.